ACAD
31.44
+0.5
+1.62%
AEMD
1.42
-0.09
-5.96%
APRI
1.48
0.00
0.00%
ARNA
21.02
+0.76
+3.75%
ATEC
1.96
+0.02
+1.03%
CNAT
5.18
+0.03
+0.58%
CRXM
0.172
+0.002
+1.1176%
CYTX
0.321
+0.01
+3.149%
DXCM
75.91
+2.85
+3.90%
GNMK
9.44
-0.1
-1.05%
HALO
12.1
+0.2
+1.68%
ILMN
194.76
+4.08
+2.14%
INNV
0.117
+0.009
+8.837%
INO
5.56
+0.1
+1.83%
ISCO
1.2
-0.05
-4.00%
ISIS
57.56
0.00
0.00%
LGND
127.97
+1.42
+1.12%
LPTN
2.93
-2.93
-100.00%
MBVX
0.51
0.00
0.00%
MEIP
2.58
-0.02
-0.77%
MNOV
5.05
+0.08
+1.61%
MRTX
5.3
-0.15
-2.75%
MSTX
0.13
-0.01
-5.28%
NBIX
52.62
+0.49
+0.94%
NUVA
64.65
+0.17
+0.26%
ONCS
0.94
+0.05
+5.61%
ONVO
1.96
+0.15
+8.29%
OREX
2.34
-0.05
-2.09%
OTIC
20.35
+0.1
+0.49%
QDEL
33.48
+0.71
+2.17%
RCPT
231.96
0.00
0.00%
RGLS
0.86
+0.01
+1.61%
RMD
74.55
+1.11
+1.51%
SCIE
0
0.00
0.00%
SPHS
1.89
+0.07
+3.85%
SRNE
1.7
0.00
0.00%
TROV
0.85
+0.03
+3.66%
VICL
2.37
+0.03
+1.28%
VOLC
18
0.00
0.00%
ZGNX
12.45
+0.15
+1.22%
ACAD
31.44
+0.5
+1.62%
AEMD
1.42
-0.09
-5.96%
APRI
1.48
0.00
0.00%
ARNA
21.02
+0.76
+3.75%
ATEC
1.96
+0.02
+1.03%
CNAT
5.18
+0.03
+0.58%
CRXM
0.172
+0.002
+1.1176%
CYTX
0.321
+0.01
+3.149%
DXCM
75.91
+2.85
+3.90%
GNMK
9.44
-0.1
-1.05%
HALO
12.1
+0.2
+1.68%
ILMN
194.76
+4.08
+2.14%
INNV
0.117
+0.009
+8.837%
INO
5.56
+0.1
+1.83%
ISCO
1.2
-0.05
-4.00%
ISIS
57.56
0.00
0.00%
LGND
127.97
+1.42
+1.12%
LPTN
2.93
-2.93
-100.00%
MBVX
0.51
0.00
0.00%
MEIP
2.58
-0.02
-0.77%
MNOV
5.05
+0.08
+1.61%
MRTX
5.3
-0.15
-2.75%
MSTX
0.13
-0.01
-5.28%
NBIX
52.62
+0.49
+0.94%
NUVA
64.65
+0.17
+0.26%
ONCS
0.94
+0.05
+5.61%
ONVO
1.96
+0.15
+8.29%
OREX
2.34
-0.05
-2.09%
OTIC
20.35
+0.1
+0.49%
QDEL
33.48
+0.71
+2.17%
RCPT
231.96
0.00
0.00%
RGLS
0.86
+0.01
+1.61%
RMD
74.55
+1.11
+1.51%
SCIE
0
0.00
0.00%
SPHS
1.89
+0.07
+3.85%
SRNE
1.7
0.00
0.00%
TROV
0.85
+0.03
+3.66%
VICL
2.37
+0.03
+1.28%
VOLC
18
0.00
0.00%
ZGNX
12.45
+0.15
+1.22%
Home » Archive by Category

News

San Diego biotech news from BioSpace, Xconomy, PR Newswire, Marketwired and other sources, click on headlines to read the full story.

Orexigen Therapeutics to Provide Business Update and Discuss Fourth Quarter and Full Year 2015 Financial Results on February 26, 2016

February 19, 2016 – 6:30 am

SAN DIEGO, Feb. 19, 2016 /PRNewswire/ — Orexigen Therapeutics, Inc. (Nasdaq: OREX) will announce corporate and financial results for the fourth quarter and full year 2015 on Friday, February 26 before the market opens. Following the announcement, …

eFFECTOR Therapeutics Increases its Series B Financing Round to $56M

February 19, 2016 – 5:30 am

SAN DIEGO, Feb. 19, 2016 /PRNewswire/ — eFFECTOR Therapeutics, Inc., a biopharmaceutical company developing selective translation regulators for the treatment of cancer, today announced it has increased its Series B financing to a total of $56M. The new funding came from Sectoral Asset Management, a new investor in the syndicate, as well as existing investors. In conjunction with the increase, eFFECTOR has appointed Maha Katabi, Ph.D., CFA, partner, private equity at Sectoral Asset Management, to its board of directors. These developments further position eFFECTOR to pursue comprehensive clinical development of its lead product candidate, eFT508, a potent, highly selective, and orally bioavailable MNK1 and MNK2 inhibitor, across multiple tumor types. The funds will also be used to advance the company’s discovery pipeline addressing additional targets.

eFT508 is currently being evaluated in an open-label Phase 1/2 trial in patients with advanced solid tumors.  The company expects to file a second IND for eFT508 in lymphoma in the first half of 2016 and open expansion arms in specific solid tumors as well as lymphoma. The company also plans to declare its second development candidate later this year.

“Cancer has proven to be a very difficult disease,” said Steve Worland, Ph.D., president and CEO of eFFECTOR. “If we are going to bring more effective therapy to patients, we need to think strategically about new approaches to treatment. Translation regulation targets such as MNK1 and MNK2, which simultaneously regulate multiple cancer-driving and immune-signaling pathways, are an ideal way to pursue this need. With this financial backing, eFFECTOR can make significant progress developing eFT508 and the remainder of our pipeline.”

Added Dr. Katabi, “Sectoral selects investments in healthcare companies developing products that can make a meaningful impact on the patients and healthcare systems they serve. Translation control is one of the most intriguing fields of research in oncology. We are very pleased to work with the experienced team of eFFECTOR to make eFT508 the first pharmacological treatment to affect the gene translation machinery, and develop a drug useful to patients with different types of cancer.”

About eFFECTOR Therapeutics

eFFECTOR Therapeutics is pioneering the discovery and development of selective translation regulators as a new class of small molecule therapeutics for cancer. The company’s investigational compounds are designed to restore translational control to halt underlying disease mechanisms while preserving healthy physiological processes. eFFECTOR’s lead drug candidate, eFT508, is a highly selective MNK1 and MNK2 inhibitor. MNK1 and 2 are kinases that act as signal integrators at the convergence of multiple oncogenic and immune signaling pathways to regulate production of disease-driving proteins. The company has additional translation regulation programs currently in discovery. eFFECTOR has raised $111M in financing from top-tier private and corporate venture funds. For more information visit www.effector.com

Contact 
Heidi Chokeir, Ph.D.
619-849-5377 
heidi@canalecomm.com

Logo – http://photos.prnewswire.com/prnh/20150619/224279LOGO

 

SOURCE eFFECTOR Therapeutics

Veracyte Announces Publication of Study Reinforcing the Clinical Utility of the Afirma® Gene Expression Classifier in Thyroid Cancer Diagnosis

February 19, 2016 – 5:30 am

SOUTH SAN FRANCISCO, Calif., Feb. 19, 2016 /PRNewswire/ — Veracyte, Inc. (NASDAQ: VCYT), a molecular diagnostics company pioneering the field of molecular cytology, announced that an independent clinical utility study reinforcing the ability of the Afirma Gene Expression Classifier (GEC) to significantly reduce unnecessary surgeries in thyroid cancer diagnosis was published in the February issue of
Cancer Cytopathology.

Researchers from the David Geffen School of Medicine at the University of California at Los Angeles evaluated all thyroid nodule fine needle aspirations (FNAs) performed during a 20-month period following introduction of the Afirma GEC at the institution to determine its impact on clinical practice. The genomic test is used when patients’ thyroid nodule FNA results are deemed inconclusive by traditional cytopathology and helps identify patients whose thyroid nodules are actually benign – and who can thus safely avoid unnecessary diagnostic surgery.

Among 174 patients with indeterminate cytopathology results during the study period, the Afirma GEC identified 80 as benign (46 percent) and, of the five patients with benign Afirma GEC results who underwent surgery, all five nodules proved to be benign based on the histopathology findings. Additionally, in the two primary categories of indeterminate results (“AUS-FLUS” and “SFN-FN”), use of the Afirma GEC reduced overall surgeries – among all patients tested, regardless of test results – from 49 percent to 33 percent and from 63 percent to 50 percent, respectively. Similarly, use of the genomic test increased the overall rate of cancer found when surgery was performed, from 35 percent to 47 percent for AUS-FLUS and from 33 percent to 50 percent for SFN-FN cases, respectively.

In the paper, the authors conclude, “Finally, the question remains whether Afirma GEC testing has refined the indeterminate thyroid category in cytology. The answer in our opinion is a qualified ‘yes’ because it excludes approximately 40 percent to 50 percent of the benign cases from surgery and results in a relatively higher percentage of malignant lesions in the surgical outcome.”

“These findings further reinforce the role of the Afirma GEC as a new standard of care in thyroid cancer diagnosis, where it has helped tens of thousands of patients across the country avoid unnecessary thyroid surgery, and the morbidity and anxiety that can accompany such surgery, while also reducing healthcare costs,” said Bonnie Anderson, president and chief executive officer of Veracyte.

According to the American Cancer Society, thyroid cancer is the fastest-increasing cancer in the United States, with more than 64,000 new cases expected in 2016. Among the approximately 525,000 fine-needle aspirations performed on patients with thyroid nodules each year in the United States, 15-30 percent of the results are inconclusive in ruling out cancer, and most physicians have traditionally recommended thyroid surgery for final diagnosis. Following surgery, however, 70-80 percent of these patients’ nodules are diagnosed as benign.

About Afirma 
Veracyte’s Afirma Thyroid FNA Analysis is a comprehensive solution for improved thyroid nodule assessment. It centers on the Afirma Gene Expression Classifier, a 142-gene molecular test that identifies benign thyroid nodules among those deemed indeterminate by cytopathology, enabling these patients to potentially avoid an unnecessary surgery. An additional 25 genes are used to differentiate uncommon neoplasm subtypes. The company’s Afirma Malignancy Classifiers – comprising tests for medullary thyroid cancer and BRAF gene mutation status – are designed to inform surgical strategy for those patients headed to surgery based on their cytopathology or Afirma GEC results. 

About Veracyte
Veracyte (NASDAQ: VCYT) is pioneering the field of molecular cytology, offering genomic solutions that resolve diagnostic ambiguity and enable physicians to make more informed treatment decisions at an early stage in patient care. By improving preoperative diagnostic accuracy, the company aims to help patients avoid unnecessary invasive procedures while reducing healthcare costs. Veracyte’s Afirma Thyroid FNA Analysis centers on the proprietary Afirma Gene Expression Classifier and is becoming a new standard of care in thyroid nodule assessment. The Afirma test is recommended in leading practice guidelines and is covered for nearly 175 million lives in the United States, including through Medicare and many commercial insurance plans. Veracyte is expanding its molecular cytology franchise to other clinical areas, beginning with difficult-to-diagnose lung diseases. In April 2015, the company launched the Percepta
®
Bronchial Genomic Classifier, a test to evaluate patients with lung nodules that are suspicious for cancer. Veracyte is developing a second product in pulmonology, targeting interstitial lung diseases, including idiopathic pulmonary fibrosis. For more information, please visit www.veracyte.com.

Cautionary Note Regarding Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: “anticipate,” “intend,” “plan,” “expect,” “believe,” “should,” “may,” “will” and similar references to future periods. Examples of forward-looking statements include, among others, statements we make regarding our beliefs regarding the drivers of adoption of Afirma, our expectations with respect to the success of our entry into the pulmonology market, our expectations regarding full-year 2015 guidance and forecast for annual GEC test volume, and the value and potential of our technology and research and development pipeline. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, anticipated events and trends, the economy and other future conditions. Forward-looking statements involve risks and uncertainties, which could cause actual results to differ materially, and reported results should not be considered as an indication of future performance. These risks and uncertainties include, but are not limited to: our limited operating history and history of losses; our ability to increase usage of and reimbursement for Afirma and to obtain reimbursement for any future products we may develop or sell; our ability to continue our momentum and growth; our dependence on a few payers for a significant portion of our revenue; the complexity, time and expense associated with billing and collecting from payers for our tests; laws and regulations applicable to our business, including potential regulation by the Food and Drug Administration or other regulatory bodies; our dependence on strategic relationships and our ability to successfully convert new accounts resulting from such relationships; our ability to develop and commercialize new products and the timing of commercialization; our ability to successfully achieve adoption of and reimbursement for our Percepta
®
 Bronchial Genomic Classifier; our ability to achieve sales penetration in complex commercial accounts; the occurrence and outcome of clinical studies; the timing and publication of study results; the applicability of clinical results to actual outcomes; our inclusion in clinical practice guidelines; the continued application of clinical guidelines to our products; our ability to compete; our ability to expand into international markets and achieve adoption of our tests in such markets; our ability to obtain capital when needed; and other risks set forth in the company’s filings with the Securities and Exchange Commission, including the risks set forth in the company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2015. These forward-looking statements speak only as of the date hereof and Veracyte specifically disclaims any obligation to update these forward-looking statements.

Veracyte, Afirma, Percepta, the Veracyte logo, and the Afirma logo are trademarks or registered trademarks of Veracyte, Inc.

 

SOURCE Veracyte

West Coast Bio Roundup: CRISPR Patent, HCV Data, Verily Digs & More

February 19, 2016 – 4:15 am

Pouring rain? Hailstorms? Record-setting heat? Freakin’ gnarly wipeouts on killer waves? Desert blooms stretching for miles? Bald eagles stuck in trees? Yeah, we got those. Welcome to February…

[[Click headline to continue reading.]]

Orexigen Therapeutics to Speak at the RBC Capital Markets 2016 Healthcare Conference

February 18, 2016 – 3:00 pm

SAN DIEGO, Feb. 18, 2016 /PRNewswire/ — Orexigen Therapeutics, Inc. (Nasdaq: OREX) today announced that management will participate in a fireside chat discussion at the RBC Capital Markets 2016 Healthcare Conference in New York. The discussion is scheduled for Wednesday, February 24th, at 3:05 p.m. ET.

To listen to the live webcast or a replay of the discussion, please visit the Investors section of the Company’s Web site at www.orexigen.com. A replay will be available for 14 days after the event.

 

Orexigen Contact:

Media Contact:

McDavid Stilwell

Julie Normart

VP, Corporate Communications and Business Development

BrewLife

(858) 875-8629

(415) 946-1087

mstilwell@orexigen.com

jnormart@brewlife.com

 

SOURCE Orexigen Therapeutics, Inc.

Aethlon Medical To Present At 4th Annual Sachs Cancer Bio Partnering & Investment Forum On February 24, 2016

February 18, 2016 – 7:30 am

SAN DIEGO, Feb. 18, 2016 /PRNewswire/ — Aethlon Medical, Inc. (Nasdaq: AEMD), today announced that Jim Joyce, Chairman and CEO, will be presenting at the 4th Annual Sachs Cancer Bio Partnering & Investment Forum at the New York Academy of Sciences in New York, NY at 2:20 p.m. ET on Wednesday, February 24, 2016. 

About Aethlon Medical, Inc.

Aethlon Medical creates affinity biofiltration devices to treat life-threatening diseases. The Aethlon Hemopurifier® is a leading broad-spectrum treatment countermeasure against infectious viral pathogens.  The device, which has been successfully administered to individuals infected with HIV, Hepatitis C (HCV) and Ebola virus, is currently the subject of FDA approved clinical studies. Aethlon is also studying the potential use of the Hemopurifier® to address exosomes secreted by tumors to promote the spread of metastasis and suppress the immune system of cancer patients.  The Company provides government contracting services to the Defense Advanced Research Projects Agency (DARPA) related to the development of a biofiltration device to treat sepsis and maintains majority ownership of Exosome Sciences, Inc., which is focused on the discovery of exosomal biomarkers to diagnose and monitor Chronic Traumatic Encephalopathy (CTE) and other neurological disorders.  Additional information can be found online at www.AethlonMedical.com or you can connect with us on Twitter, LinkedIn, Facebook and Google+.

About the 4th Annual Sachs Cancer Bio Partnering & Investment Forum

The 4th Annual Sachs Cancer Bio Partnering & Investment Forum is designed to bring together thought leaders from cancer research institutes, patient advocacy groups, pharmaceutical, and biotech to facilitate partnering and funding/investment. The conference will attract approximately 250 delegates and 30 company presentations by listed and private biotechnology companies seeking licensing and investment opportunities. The event provides a platform for one-on-one meetings and dedicated meeting facilities to make the event more productive. For more information, please visit: http://www.sachsforum.com/.

Contacts:

Mike Smargiassi/Brad Edwards
Brainerd Communicators, Inc
212-986-6667
smarg@braincomm.com

Photo – http://photos.prnewswire.com/prnh/20090325/LA88762LOGO-b

 

SOURCE Aethlon Medical, Inc.

Rebels with a Cause

February 18, 2016 – 7:00 am

They clicked immediately, as though long-lost brothers. Gerardo Arellano and Gabriel Agundez were best friends and roommates who bonded over house music and political activism as undergraduates at UC San Diego more than 20 years ago. They reunited at a recent event at the campus Raza Resource Centro, which Arellano now directs. Agundez was there with his step-son, Christian Sanabria, a new transfer student. He told Arellano he was entrusting him—and the university—with his son, to gain the student experience they lacked.

Forge Therapeutics to Present at the BIOCOM Global Life Science Partnering Conference

February 18, 2016 – 6:00 am

SAN DIEGO, Feb. 18, 2016 /PRNewswire/ — Forge Therapeutics, Inc., a biotechnology company discovering innovative therapeutics using a breakthrough drug discovery platform targeting metalloproteins, announced today that Zachary Zimmerman, Ph.D., Chief Executive Officer, will present a corporate overview at the BIOCOM Life Science Partnering Conference being held at the Lodge at Torrey Pines, San Diego, CA on February 24th & 25th, 2016. 

“It is an honor to be selected to present at this prestigious partnering conference that attracts life science executives from around the globe to visit San Diego and become inspired by our vibrant biotech ecosystem,” said Zachary A. Zimmerman, Ph.D., CEO of Forge Therapeutics.  “This is a great opportunity to showcase the Forge technology and our leading efforts in Gram-negative bacteria where we have developed the first non-hydroxamate inhibitor of LpxC that is potent in cells, including multi-drug resistant superbugs, and efficacious in vivo.” 

The presentation will include an overview of Forge’s metalloprotein technology platform, lead therapeutic programs in Gram negative bacteria, epigenetics, and cancer immunity, as well as financing and partnering strategies.

Details of Forge’s presentation:

Event: 

BIOCOM Life Science Partnering Conference

Date: 

Wednesday, February 24th

Time: 

10:40 AM PST

Location: 

Alfred Mitchell Room

 

About Forge Therapeutics, Inc.

Forge Therapeutics, Inc. (“Forge”) is a biotechnology start-up that leverages its novel chemistry platform to develop small molecule inhibitors to target metalloproteins.  Metalloproteins are proteins that require metal ions for their biological function and make up over 1/3 of the proteins in the human body.  Forge uses a proprietary approach comprised of molecular modeling for rational drug design along with fundamental knowledge and expertise in bioinorganic chemistry to target metalloproteins.  The name Forge Therapeutics comes from two definitions for forge: to manipulate (inhibit) a metal object (metalloprotein) and to move forward steadily with a purpose (the Forge team).  Forge Therapeutics, Inc., maintains its headquarters in San Diego, California.  To learn more please visit www.ForgeTherapeutics.com

About BIOCOM Global Life Science Partnering Conference

In its 6th Year, the BIOCOM Global Life Science Partnering Conference is an exclusive partnering forum that provides senior executives, bankers, venture capitalists, and business development professionals from the leading pharmaceutical and biotech companies to network and do business with one another from around the globe.  To learn more please visit http://biocomglobalpartnering.org/

Contact:
Info@ForgeTherapeutics.com

Logo – http://photos.prnewswire.com/prnh/20150807/256906LOGO

 

SOURCE Forge Therapeutics, Inc.

OncoSec to Host Second Quarter Financial Results Conference Call on March 8, 2016

February 18, 2016 – 4:00 am

SAN DIEGO, Feb. 18, 2016 /PRNewswire/ — OncoSec Medical Incorporated (“OncoSec”) (NASDAQ: ONCS), a company developing DNA-based intratumoral cancer immunotherapies, today announced that the Company will host its fiscal second quarter 2016 financial results conference call on Tuesday, March 8 at 1:15 PM PT/4:15 PM ET. To listen to the conference call, please dial (877) 731-1960 and use conference ID number: 50125992. An archived version of the presentation will be available for 90 days on the “Investors” section of OncoSec’s website: ir.oncosec.com/events.

About OncoSec Medical Incorporated
OncoSec is a biotechnology company developing DNA-based intratumoral immunotherapies with an investigational technology, ImmunoPulse™, for the treatment of cancer.  ImmunoPulse™ is designed to enhance the local delivery and uptake of DNA-based immune-targeting agents, such as IL-12. In Phase I and II clinical trials, ImmunoPulse™ IL-12 has demonstrated a favorable safety profile and evidence of anti-tumor activity in the treatment of various skin cancers as well as the potential to initiate a systemic immune response. OncoSec’s lead program, ImmunoPulse™ IL-12, is currently in Phase II development for several indications, including metastatic melanoma, squamous cell carcinoma of the head and neck, and triple-negative breast cancer. In addition to ImmunoPulse™ IL-12, the Company is also identifying and developing new immune-targeting agents for use with the ImmunoPulse™ platform. For more information, please visit www.oncosec.com.

Contact
Mary Marolla
OncoSec Medical Incorporated
855-662-6732
media@oncosec.com

Logo – http://photos.prnewswire.com/prnh/20120905/LA68078LOGO

 

SOURCE OncoSec Medical Incorporated

ViaCyte to Present at Upcoming Healthcare Events

February 17, 2016 – 7:00 am

SAN DIEGO, Feb. 17, 2016 /PRNewswire/ — ViaCyte, Inc., a privately-held regenerative medicine company with the first pluripotent stem cell-derived islet replacement therapy for the treatment of diabetes in clinical-stage development, today announced three presentations at upcoming healthcare events.

Details of the presentations are as follows:

Event:        

Regenerative Medicine: Transitioning Therapeutics from Cells to the Clinic

Title:           

Development of Stem-Cell Derived, Macroencapsulated Islet Replacement for Type 1 Diabetes

Speaker:      

Dr. Thomas Schulz, Director, ES Cell Technology

Date/Time:     

February 22, 2:35 p.m. EST

Location:        

New York Academy of Sciences Conference Center, New York, NY

Event:             

The 2nd Saudi International Biotechnologies Conference 2016

Title:               

Chasing a Cure for Type 1 Diabetes: The Development of a Stem Cell Derived Islet Replacement Therapy

Speaker:         

Dr. Paul Laikind, President and CEO

Date/Time:     

February 23, 9:15 a.m. AST

Location:        

KACST Headquarters, Conference Hall, Riyadh, Saudi Arabia

Event:             

American Society of Transplantation: Pipeline Presenters

Speaker:         

Dr. Kevin D’Amour, Vice President, Research and CSO

Date/Time:     

February 25, 11:00 a.m. MST

Location:        

Arizona Biltmore, Phoenix, Arizona

ViaCyte’s VC-01™ product candidate, a first-in-class cell replacement therapy for the treatment of type 1 diabetes, is currently being evaluated in a Phase 1/2 trial called STEP ONE, or Safety, Tolerability, and Efficacy of VC-01 Combination Product in Type One Diabetes.  More info on the clinical trial is here: https://clinicaltrials.gov/ct2/show/NCT02239354.

For more information about ViaCyte’s participation in industry events, please visit: http://viacyte.com/news-events-2/viactye-events/

About ViaCyte

ViaCyte is a privately-held regenerative medicine company focused on developing a novel cell replacement therapy for the treatment of diabetes.  ViaCyte is conducting a Phase 1/2 clinical trial of the Company’s lead VC-01 product candidate in patients with type 1 diabetes who have minimal to no insulin-producing beta cell function.  ViaCyte’s VC-01 combination product candidate is based on the production of pancreatic progenitor cells derived from human pluripotent stem cells.  These progenitor cells are implanted in a durable and retrievable encapsulation device.  Once implanted and matured, these cells are designed to secrete insulin and other regulatory factors in response to blood glucose levels.  The VC-01 product candidate is being developed as a potential long-term diabetes treatment with the goal of reducing the risk of hypoglycemia and diabetes-related complications without requiring long-term immune suppression. 

ViaCyte is headquartered in San Diego, California with additional operations in Athens, Georgia.  The Company is funded in part by the California Institute for Regenerative Medicine (CIRM) and JDRF. 

For more information please visit www.viacyte.com.  Connect with ViaCyte here: www.twitter.com/viacyte and www.facebook.com/viacyte.

Logo – http://photos.prnewswire.com/prnh/20121026/LA00871LOGO-a

 

SOURCE ViaCyte, Inc.